Exploring the Impact of Once-Daily OROS® Methylphenidate (MPH) on Symptoms and Quality of Life in Children and Adolescents with ADHD Transitioning from Immediate-Release MPH

References

• . Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: Is it an American condition? World Psychiatry. 2003; 2(2):104–113
   PubMedGoogle Scholar
• . Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005; 366(9481):237–248
   PubMed Web of Science ®Google Scholar
• . Polancszyk G, de Limas MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry. 2007; 164(6):942–948
   PubMed Web of Science ®Google Scholar
• . Wilens TE, Dodson W. A clinical perspective of attention-deficit/hyperactivity disorder into adulthood. J Clin Psychiatry. 2004; 65(10):1301–1313
   PubMed Web of Science ®Google Scholar
• . Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult outcome of hyperactive children: Adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry. 2006; 45(2):192–202
   PubMed Web of Science ®Google Scholar
• . Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ. Modifers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: Does treatment with stimulant medication make a difference? Results from a population-based study. J Dev Behav Pediatr. 2007; 28(4):274–287
   PubMed Web of Science ®Google Scholar
• . Hechtman L. Assessment and diagnosis of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 2000; 9(3):481–498
   PubMed Web of Science ®Google Scholar
• . Johnson C, Marsh EJ. Families with children with ADHD: Review and recommendations for future research. Clin Child Fam Psychol Rev. 2001; 4(3):183–207
   PubMed Web of Science ®Google Scholar
• . Escobar R, Soutullo CA, Hervas A, Gastaminza X, Polavieja P, Gilaberte I. Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics. 2005; 116(3):e364–e369
   PubMed Web of Science ®Google Scholar
• . McClure A, Prasad S, Poole L. Functional outcomes of children with attention deficit/hyperactivity disorder in the UK. Arch Dis Childhood. 2005; 90:A48–A50
   PubMedGoogle Scholar
• . Benkert D, Krause KH, Wasem J, Aidelsburger P. Effectiveness of pharmaceutical therapy of ADHD (Attention-deficit/Hyperactivity Disorder) in adults — health technology assessment. DIMDI 2010; 108. http://portal.dimdi.de/de/hta/hta_berichte/hta267. Accessed December 21, 2010
   Google Scholar
• . Canadian Attention deficit Hyperactivity Disorder Resource Alliance (CADDRA). Canadian ADHD practice guidelines, CADDRA 2008. http://www.caddra.ca. Accessed December 16, 2009
   Google Scholar
• . National Institute for Health and Clinical Excellence (NICE). Attention-deficit/hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults, September 2008. http://www.nice.org.uk. Accessed December 16, 2009
   Google Scholar
• . Coghill D, Seth S. Osmotic, controlled-release methylphenidate for the treatment of ADHD. Expert Opin Pharmacother. 2006; 7(15):2119–2139
   PubMed Web of Science ®Google Scholar
• . Swanson J. Compliance with stimulants for attention-deficit/hyperactivity disorder: Issues and approaches for improvement. CNS Drugs. 2003; 17(2):117–131
   PubMed Web of Science ®Google Scholar
• . Swanson J, Gupta S, Lam A, . Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: Proof-of-concept and proof-of-product studies. Arch Gen Psychiatry.2003; 60(2):204–211
   PubMed Web of Science ®Google Scholar
• . Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized, controlled, effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol. 2006; 13:e50–e62
   PubMedGoogle Scholar
• . Gau SS, Shen HY, Soong WT, Gau CS. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Child Adolesc Psychopharmacol. 2006; 16(4):441–455
   PubMed Web of Science ®Google Scholar
• . Chou WJ, Chou MC, Tzang RF, . Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. Psychiatry Clin Neurosciences. 2009; 63(2):167–175
   PubMed Web of Science ®Google Scholar
• . Kim Y, Shin MS, Kim JW, Yoo HJ, Cho SC, Kim BN. Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD. Hum Psychopharmacol Clin Exp. 2009; 24(2):95–102
   PubMed Web of Science ®Google Scholar
• . Buitelaar J, Medori R. Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: A review of the potential benefits of long-acting stimulants. Eur Child Adolesc Psychiatry. 2010; 19(4):325–340
   PubMed Web of Science ®Google Scholar
• . Danckaerts M, Sonuga-Barke EJ, Banaschewski T, . The quality of life of children with attention deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2010; 19(2):83–105
   PubMed Web of Science ®Google Scholar
• . Conners CK. Rating scales in attention-deficit/hyperactivity disorder: Use in assessment and treatment monitoring. J Clin Psychiatry. 1998; 59( suppl 7):24–30
   PubMed Web of Science ®Google Scholar
• . Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised Conners' parent rating scale (CPRS-R): Factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998; 26(4):257–268
   PubMed Web of Science ®Google Scholar
• . Conners CK. Clinical use of rating scales in diagnosis and treatment of attention-deficit/hyperactivity disorder. Pediatr Clin North Am. 1999; 46(5):857–870
   PubMed Web of Science ®Google Scholar
• . Mattejat F, Jungmann J, Meusers M, . An inventory for assessing the quality of life of children and adolescents—a pilot study [in German]. Z Kinder Jugendpsychiatr Psychother. 1998; 26(3):174–182
   PubMed Web of Science ®Google Scholar
• . Mattejat F, Simon B, König U, . Quality of life of children and adolescents with psychiatric disorders. Results of the 1st multicenter study with an inventory to assess the quality of life in children and adolescents [in German]. Zeitschrift für Kinder- und Jugendpsychiatrie. 2003; 31(4):293–303
   Google Scholar
• . Ehnis P, Trosse M, Remschmidt H. Life quality of children and adolescents in Germany. Results of a representative telephone survey. In: Remschmidt H, Belfer M, eds. 16th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions, August 22–26, 2004. Stuttgart, Germany: Steinkopf; 2004:374
   Google Scholar
• . Mattejat F, Remschmidt H. Das Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK) [The Inventory of Life Quality in Children and Adolescents (ILC)]. Bern, Switzerland: Verlag Hans Huber; 2006
   Google Scholar
• . Jozefak T, Larsson B, Wichstrøm L, Mattejat F, Ravens-Sieberer U. Quality of life as reported by school children and their parents: A cross-sectional survey. Health Qual of Life Outcomes. 2008; 6:34
   PubMed Web of Science ®Google Scholar
• . Shaffer D, Gould MS, Brasic J, . A children's global assessment scale (CGAS). Arch Gen Psychiatry. 1983; 40(11):1228–1231
   PubMed Web of Science ®Google Scholar
• . Remschmidt H, Hoare P, Ettrich C, . Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS® MPH. Results of a 3-week open-label study. Eur Child Adolesc Psychiatry. 2005; 14(6):297–304
   PubMed Web of Science ®Google Scholar
• . Sanchez RJ, Crismon ML, Barner JC, Bettinger T, Wilson JP. Assessment of adherence measures with different stimulants among children and adolescents. Pharmacotherapy. 2005; 25(7):909–917
   PubMed Web of Science ®Google Scholar
• . Sasané R, Hodgkins P, Meijer W. Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: Data from the Netherlands. Curr Med Res Opin. 2010; 26(11):2565–2574
   PubMed Web of Science ®Google Scholar
• . Landgraf J, Abetz L, Ware JE. The CHQ User's Manual. Boston, MA: Health Institute; 1996
   Google Scholar
• . Klassen AF, Miller A, Fine S. Agreement between parent and child report of quality of life in children with attention-deficit/hyperactivity disorder. Child Care Health. 2006; 32(4):397–406
   PubMed Web of Science ®Google Scholar
• . Pelham WE, Gnagy EM, Burrows-Maclean L. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001; 107(6):E105
   PubMed Web of Science ®Google Scholar
• . Wolraich ML, Greenhill LL, Pelham W, ; Concerta Study Group: Randomized, controlled trial of OROS methylphenidate once a day in children with attention deficit/hyperactivity disorder. Pediatrics. 2001; 108(4):883–892
   PubMed Web of Science ®Google Scholar